These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11103753)

  • 21. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
    Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
    J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
    Gottdiener JS
    Circulation; 1999 Aug; 100(6):685-6. PubMed ID: 10490345
    [No Abstract]   [Full Text] [Related]  

  • 23. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
    Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased renal production of angiotensin II and thromboxane B2 in conscious diabetic rats.
    Awad AS; Webb RL; Carey RM; Siragy HM
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):544-8. PubMed ID: 15831366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats.
    Chan P; Liu IM; Tzeng TF; Yang TL; Cheng JT
    Diabetes Obes Metab; 2007 Jan; 9(1):39-49. PubMed ID: 17199717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
    Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.
    Saiki A; Ohira M; Endo K; Koide N; Oyama T; Murano T; Miyashita Y; Shirai K
    Diabetes Res Clin Pract; 2006 Dec; 74(3):242-8. PubMed ID: 16713009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan.
    Saisho Y; Komiya N; Hirose H
    Diabetes Res Clin Pract; 2006 Nov; 74(2):201-3. PubMed ID: 16737758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan.
    Daneshtalab N; Lewanczuk RZ; Russell A; Jamali F
    J Clin Pharmacol; 2004 Mar; 44(3):245-52. PubMed ID: 14973301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects.
    Müller P; Flesch G; de Gasparo M; Gasparini M; Howald H
    Eur J Clin Pharmacol; 1997; 52(6):441-9. PubMed ID: 9342579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding.
    Maillard MP; Rossat J; Brunner HR; Burnier M
    J Pharmacol Exp Ther; 2000 Nov; 295(2):649-54. PubMed ID: 11046101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential effect of acute angiotensin II type 1 receptor blockade on the vascular and adrenal response to exogenous angiotensin II in humans.
    Lottermoser K; Unger T; Gohlke P; Vetter H; Düsing R
    Am J Hypertens; 2003 Jun; 16(6):445-52. PubMed ID: 12799092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal angiotensin II in humans reduces blood pressure when angiotensin II type 1 receptors are blocked.
    Derad I; Sayk F; Lehnert H; Marshall L; Born J; Nitschke M
    Hypertension; 2014 Apr; 63(4):762-7. PubMed ID: 24420549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin II increases the release of endothelin-1 from human cultured endothelial cells but does not regulate its circulating levels.
    Ferri C; Desideri G; Baldoncini R; Bellini C; Valenti M; Santucci A; De Mattia G
    Clin Sci (Lond); 1999 Mar; 96(3):261-70. PubMed ID: 10029562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valsartan and candesartan can inhibit deteriorating effects of angiotensin II on coronary endothelial function.
    Seeger H; Lippert C; Wallwiener D; Mueck AO
    J Renin Angiotensin Aldosterone Syst; 2001 Jun; 2(2):141-3. PubMed ID: 11881114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension.
    Plum J; Bünten B; Németh R; Grabensee B
    J Am Soc Nephrol; 1998 Dec; 9(12):2223-34. PubMed ID: 9848776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Valsartan inhibits angiotensin II-stimulated proliferation of smooth muscle cells from human coronary artery.
    Mueck AO; Seeger H; Lippert TH
    Int J Clin Pharmacol Ther; 1999 Jul; 37(7):365-6. PubMed ID: 10442512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade.
    Awad AS; Webb RL; Carey RM; Siragy HM
    J Hypertens; 2004 Aug; 22(8):1571-7. PubMed ID: 15257181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway.
    Gossmann J; Burkhardt R; Harder S; Lenz T; Sedlmeyer A; Klinkhardt U; Geiger H; Scheuermann EH
    Kidney Int; 2001 Jul; 60(1):83-6. PubMed ID: 11422739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nitrite, endothelin and E-selectin plasma levels after arginine infusion in normal and vasculopathic subjects.
    Ferlito S; Gallina M
    Minerva Cardioangiol; 1998 Dec; 46(12):471-7. PubMed ID: 10209938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.